Omeros appoints David Mann to Board

Friday 15 August 2008
Zoe Dann - Production Editor

Omeros (US), a clinical-stage biopharmaceutical company discovering, developing and commercialising products focused on inflammation and disorders of the central nervous system, has appointed David Mann to its board of directors. He also serves as chairman of the board's audit committee. Mr Mann has more than 20 years' executive management, finance and operations experience in the biotechnology industry. He was executive vice-president and chief financial officer at Immunex before and during its acquisition by Amgen, and held senior financial positions at the Fred Hutchinson Cancer Research Center.

• Not a subscriber? Request a FREE trial
• Subscribe to Scrip
• Email to a friend

• Facebook
• digg
• del.icio.us
• furl